Aethlon Medical, Inc. (OTCMKTS:AEMD) starts the week off in consolidation mode after the run to highs of $0.72 last week. Investors are waiting for a break over recent highs for confirmation of the next leg up.
AEMD has made one of those legendary runs that we love to report on exploding off its base at $0.10 to recent highs of $0.72 a share. The run was marked by massive volume and it transformed AEMD from obscurity to become one of the top traded stocks on the entire bb’s.
Recent significant developments for AEMD include Time Magazine Naming The Aethlon Hemopurifier® One of the 25 Best Inventions of 2014 and AEMD announcing that the Ebola patient who received Hemopurifier® therapy has been reported to have been discharged from Frankfurt University Hospital in Germany. The patient was a Ugandan physician, who became infected with Ebola in Sierra Leone where he was treating other Ebola patients.
The story on AEMD is their bio-filtration device, the Aethlon Hemopurifier® which they have successfully used to treat a critically-ill Ebola-infected patient in Frankfurt, Germany.
The patient was a Ugandan Doctor, who was infected with Ebola in Sierra Leone where he was treating Ebola patients. At the time of treatment, which occurred at Frankfurt University Hospital, the patient was unconscious and suffering from multiple organ failure.
According to recent data which Aethlon presented at the American Society of Nephrology (ASN) Annual Meeting ” 242 million Ebola viruses were captured within the Aethlon Hemopurifier® during treatment, a number verified by a post-treatment elution protocol. The patient is no longer infected with Ebola virus and is expected to make a full recovery.
Since Aethlon completed the first treatment in mid-October the stock has exploded more than 4 fold off its base at a dime and has quickly become one of the top 3 most traded stocks on the entire OTCBB market.
Aethlon Medical, Inc. (OTCMKTS:AEMD) is a San Diego, California based Medical Device Company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions.
At the core of Aethlon is their Adaptive Dialysis-Like Affinity Platform Technology System (ADAPT™) a medical device platform that converges single or multiple affinity drug agents with advanced plasma membrane technology to create therapeutic filtration devices that selectively remove harmful particles from the entire circulatory system without loss of essential blood components.
They developed the Aethlon Hemopurifier® a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.
To Get the Inside Scoop on Aethlon, Subscribe via email Right Now.
Back in June of this year the FDA approved an Investigational Device Exemption (IDE) that allowed Aethlon to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States.
AEMD currently averages just under $500,000 a quarter in revenues that are derived from a DARPA Government contract that was awarded to the Company back in September 2011. Under the terms of the contract Aethlon is developing a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers. The award from DARPA was a fixed-price contract with potential total payments to us of $6,794,389 over the course of five years.
We have a Monster Pick Coming. Subscribe Right Now!
On November 19 Aethlon said will provide Hemopurifier® therapy under FDA expanded access “emergency use” provisions to support requests from qualified physicians and institutes that may seek to treat Ebola virus infection in the United States.
Conclusion: Over the past few weeks AEMD has transformed from unknown and illiquid at a dime to one of the top most traded stocks on the entire OTCBB topping $0.72 a share. The parabolic move comes on massive investor interest as Aethlon successfully treats a critically-ill Ebola-infected patient with the Aethlon Hemopurifier®.
Positive news continues to flow from the Company as they expand studies for the device in the US under a new FDA Investigational Device Exemption (IDE). Currently trading at a $115 million market valuation AEMD has captured the imaginations of small cap investors and is quickly building a loyal shareholder base that swears this one goes higher.
The Ebola virus continues to rage in West Africa with 14,000 reported cases as of November 11 and 5,177 dead in six countries including Liberia, Guinea, Sierra Leone, Nigeria, the United States and Mali.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in AEMD either long or short and we have not been compensated for this article.